Pro Medicus (ASX: PME) - Investment Research Report

3-Year / 5-Year Price Scenarios

Base EPS: $1.4 — A$1.40 is a normalized starting EPS judgment: FY25 reported EPS was about A$1.11, while HY26 reported EPS was about A$1.64 because the 4D Medical investment generated a large unrealised gain. The valuation therefore does not capitalise that one-off gain.

0. Information Richness & AI Limitations

Grade A (abundant). Pro Medicus publishes audited annual accounts, reviewed interim accounts and detailed contract announcements. The latest official results calendar available at the 31 July 2026 cutoff lists FY25 annual results released 14 August 2025 and HY26 interim results released 12 February 2026. AI research confidence is high on reported history and business quality, but not on future contract timing, competitive outcomes or a fair long-term multiple. The stock is an unusually important case where excellent business quality does not automatically imply an attractive investment price.

1. Data & Cross-Validation

The independently validated 31 July 2026 quote is A$161.15. ASX's company header reported market capitalisation of about A$16.79 billion and A$160.905 during the same run; Google Finance also showed A$160.905. Using approximately 104.3 million shares, A$161.15 x 104.3m implies A$16.81 billion, within 0.2% of the ASX figure. The market therefore values PME at roughly 98x the HY26 reported EPS annualised and about 83x the normalized forward EPS assumption.

Reported financials (AUD millions): FY25 revenue was A$213.0m (+31.9%) and net profit was A$115.2m (+39.2%), with a 30c fully franked final dividend. HY26 revenue was A$124.8m (+28.4%) and underlying profit was A$67.3m (+29.7%); reported profit of A$171.2m included a A$149.1m pre-tax unrealised gain on the July 2025 4D Medical investment. HY26 underlying EBIT margin increased to 73%, cash and other financial assets reached A$221.8m, and the company remained debt-free. Primary sources: FY25 announcement and HY26 interim report.

The core cross-check is deliberately conservative: reported HY26 profit is not treated as recurring operating earnings because of the 4D fair-value gain. Contract announcements and the results releases show broad US expansion, but signed contract value is not the same as immediate revenue.

2. Business Essence - Duan Yongping

One line: Pro Medicus supplies Visage 7, a fast medical-imaging viewer, archive and workflow platform used by hospitals and radiology networks to store, retrieve and interpret diagnostic images.

The customer value is speed, reliability, lower infrastructure burden and a unified cloud workflow for large imaging datasets. Once embedded in a hospital's clinical workflow, replacement is risky and expensive, creating recurring multi-year enterprise contracts. The model combines implementation revenue with recurring software and cloud economics. The company has demonstrated pricing and operating leverage: FY25 revenue grew 31.9% while net profit grew 39.2%, and HY26 underlying EBIT margin reached 73%. The key limitation is that each new customer still requires a long sales, procurement and implementation cycle.

3. Moat - Buffett

The moat is based on switching costs, product performance, accumulated clinical trust and a small installed base of deeply integrated customers rather than a consumer network effect. A hospital's images and workflows are mission-critical; migration risk, training and interoperability make a proven platform valuable. Pro Medicus also benefits from a focused product architecture and a growing implementation record, while its debt-free balance sheet funds product development.

The moat appears to be widening as more US health systems adopt the full stack and cardiology offering. It is not invulnerable: larger imaging and healthcare-information vendors have more distribution, hospital procurement can be slow and a well-funded competitor could improve its cloud architecture. The relevant Buffett test is not whether PME has a good product today, but whether customer trust and switching costs remain strong when the installed base becomes much larger.

4. Reverse Thinking & Risks - Munger

The central inversion is simple: at nearly 100x reported trailing earnings, even a very good business can produce poor returns if growth slows or the multiple normalises. Historical analogies include high-quality software companies that continued to grow but delivered disappointing shareholder returns after being purchased at peak expectations. Disconfirming evidence would be sustained net customer losses, margin deterioration, repeated implementation delays or contract value that fails to convert into recurring revenue. The market can be right about the business and still wrong about the price.

5. Management - Duan Yongping + Buffett

CEO and co-founder Dr Sam Hupert has led the company through a long period of profitable product development and international expansion. The FY25 and HY26 announcements describe record contract wins, implementations and continued product adoption. Management has preserved a debt-free balance sheet while returning capital through fully franked dividends and share buybacks, and it has invested in adjacent cardiology capability.

The positive evidence is disciplined capital intensity, high margins and transparent separation of underlying profit from the 4D Medical fair-value gain. The caution is concentration around a small leadership group and the possibility that a strong track record encourages investors to extrapolate growth too far. Incentives and capital allocation should be monitored through dilution, acquisition spending and the conversion of announced contract value into reported recurring revenue.

6. Industry & Civilizational Trend - Li Lu

Medical imaging is a durable information infrastructure market. Aging populations, higher diagnostic volumes, cloud adoption and the need to move images across health systems support long-term demand. Pro Medicus sits in the software layer, where a successful product can scale more efficiently than physical imaging equipment.

The total addressable market is large, but not infinite: hospital buying is concentrated, regulated and budget constrained. AI-assisted imaging may increase demand for better data access and workflow, while also giving larger platforms a reason to bundle competing tools. The long-run question is whether Visage becomes an enduring standard or a valuable product inside a market that eventually consolidates around broader healthcare platforms. The opportunity is real, but the current price already assumes substantial civilizational and company-specific success.

7. Valuation & Scenarios - Buffett + Duan

PME is a quality-at-a-price situation. FY25 reported EPS was approximately A$1.11 and HY26 reported EPS approximately A$1.64, but the latter includes the one-off 4D Medical fair-value gain. I use normalized base EPS of A$1.40. That is not a forecast; it is a conservative starting point for scenario arithmetic.

3-year scenarios: bull assumes 15% EPS growth and a 65x exit P/E for A$138.40; base assumes 10% growth and 50x for A$93.20; bear assumes 5% EPS contraction and 30x for A$36.00. With probabilities of 25%, 50% and 25%, the weighted target is A$90.20, or -44.0% versus A$161.15.

5-year scenarios: bull assumes 15% growth and 65x for A$182.90; base assumes 10% growth and 50x for A$112.80; bear assumes 5% contraction and 25x for A$27.10. The weighted target is A$108.90, or -32.4%. The bull case still requires both excellent execution and a premium multiple. Dividend income is currently small at roughly 0.4%, so it cannot compensate for a valuation reset. The largest uncertainty is not whether PME can grow, but how much of that growth is already capitalised.

8. Decision Memo

Decision: avoid initiating at the cutoff price. Existing owners may hold only if they accept substantial valuation and execution risk. A more interesting accumulation zone is A$85-A$110, subject to the contract pipeline and margins remaining intact. Add on evidence of recurring revenue conversion and stable margins, not merely on another announced contract. Sell or reassess if contract wins stop translating into implementations, cloud adoption stalls, or margins fall materially. The thesis is invalidated by evidence that the platform is losing competitive relevance, not by a normal quarter of timing noise.

Four-Master Commentary (Analytical Simulations)

Buffett (analytical simulation, not a real quotation): This is a wonderful business with recurring contracts, high returns and a debt-free balance sheet. But wonderful businesses can be poor investments at prices that require everything to go right.

Munger (analytical simulation, not a real quotation): Invert the decision. The obvious way to lose is to pay a heroic multiple, then discover that a few delayed implementations or a better-funded competitor are enough to reset expectations.

Duan Yongping (analytical simulation, not a real quotation): I would admire the product and management, but insist on a reasonable price. A strong moat is not permission to ignore valuation.

Li Lu (analytical simulation, not a real quotation): Healthcare digitisation can compound for decades, but the investor's return still depends on the entry price and the margin between present value and market expectations.